Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023 By Sarah EllinwoodMay 26, 2023 Funding, Awards and Collaborations Adaptive Phage Therapeutics Partners with Hebrew University, Hadassah Medical [….]
The JP Morgan Healthcare conference (JPM23) is running January 9-13, 2023, in San Francisco. It’s one of the biggest biotech conferences, possibly the biggest, with companies from all over the world coming (or attending virtually) to network with possible investors, present their companies’ progress and breakthrough, announce their annual financial and milestone guidance, and negotiate deals.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its prespecified primary endpoint which was the difference between drug and placebo on the change of the severity of nausea from baseline at week 12 of treatment. Both treatment arms showed significant improvements from baseline on nausea as well as the other core symptoms of gastroparesis.
These Five Capital Region Biotechs Are The Fastest Growing in America December 5, 2018 In its 24th year, the Deloitte Technology Fast 500 is the premier technology awards program in [….]
